# Remission Medical, LLC.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remission-medical

- Industry: Healthcare IT
- Headquarters: Richmond, US
- Website: www.remissionmedical.com/
- Total disclosed funding: $5M
- Latest round: Series A (Apr 9, 2026)
- Investors on record: 1

## About

Based in the US, Remission Medical, LLC provides innovative rheumatology care solutions that enhance patient access and reduce appointment wait times through a comprehensive platform integrating with existing healthcare systems.Remission Medical, LLC focuses on improving rheumatology care access for patients and healthcare providers. Founded in 2021 and headquartered in Richmond, US, the company raised USD 5.000 mn in Series A funding on April 9, 2026, led by Blue Heron Capital. The company has completed one deal to date.Remission Medical specializes in a capacity-extension model designed for integration with healthcare providers' existing Electronic Health Record (EHR), scheduling, billing, and brand systems. The company's primary offering improves access to rheumatology care by reducing appointment wait times to as little as seven days, leveraging telemedicine and a network of vetted, board-certified rheumatology providers. This approach addresses significant issues such as long wait times and lack of continuity in care, benefiting health systems aiming to optimize service delivery.Remission Medical generates revenue through partnerships with health systems and specialty practices using a B2B model. Their revenue structures include transactions related to healthcare service agreements, enhancing patient outcomes while retaining revenue from ancillary services like imaging and lab tests. Health systems typically pay for access to Remission Medical’s platform, which streamlines rheumatology care and improves the overall patient experience.Following the Series A funding of USD 5.000 mn from Blue Heron Capital in April 2026, Remission Medical plans to expand health system partnerships, increase clinical staffing, and scale its operational platform to enhance rheumatology service delivery. These initiatives are aimed at broader deployment across existing markets and potentially entering new geographic regions.

## Funding rounds

- Series A, Apr 9, 2026, $5M — Blue Heron Capital

## Investors

- Blue Heron Capital (https://capitalatlas.ai/funds/blue-heron-capital) — Series A